Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...

Eosinophilic gastrointestinal diseases are exponentially more prevalent among patients with atopic diseases compared with the ...

Patients with eosinophilic esophagitis in the US have high health care resource utilization costs, according to a retrospective national claims study.

To know more about Eosinophilic Esophagitis companies working in the treatment market, visit @ Eosinophilic Esophagitis Clinical Trials and FDA Approvals Table of Contents ...

Eosinophilic Esophagitis: Empowering Clinicians for Better Patient Outcomes This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-Q) from The Globe and Mail including charting and trades.

Discover a study that highlights dupilumab’s consistent efficacy in eosinophilic oesophagitis, even among patients with ...

The clinical-stage biotechnology company said Tuesday that the study will enroll at least 60 participants who will receive either one EP-104GI dose, two doses or a placebo. After six months, eligible ...

They correlated the presence of esophageal eosinophilia (>1 eosinophil/high power field [HPF]) with markers of reflux esophagitis (abnormal pH studies, manometry and endoscopy) in 46 children.

Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease of undetermined pathophysiology that results in dense mucosal eosinophilia and esophageal dysfunction.

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best hot stocks to buy according to Wall Street analysts. Earlier in May ...